Fed’s Powell opens door to potential rate cuts at Jackson Hole
NEW BRUNSWICK, N.J. - Johnson & Johnson (NYSE: JNJ), the global healthcare company, announced on Tuesday a 4.8% increase in its quarterly dividend, a move that extends the company’s streak of consecutive annual dividend increases to 63 years.
The dividend, previously set at $1.24 per share, will be raised to $1.30 per share, resulting in an annualized payout of $5.20 per share, up from $4.96. Shareholders of record by the close of business on May 27, 2025, will be eligible for the next dividend, scheduled for payment on June 10, 2025. The company also stated that May 27, 2025, will serve as the ex-dividend date. With a moderate debt level and strong cash flows, Johnson & Johnson maintains a healthy financial position to support its dividend payments.
This announcement underscores Johnson & Johnson’s long-standing commitment to providing value to its shareholders through consistent dividend growth. The company’s ability to maintain and increase dividends over such an extended period highlights its financial stability and confidence in its future performance.
Johnson & Johnson, known for its broad range of healthcare products and services, has positioned itself as a leader in medical innovation with a focus on developing solutions for complex diseases and advancing less invasive treatments. The company’s emphasis on innovation in medicine and medical technology (MedTech) aims to profoundly impact health for humanity.
The information provided in this article is based on a press release statement from Johnson & Johnson.
In other recent news, Johnson & Johnson has been in the spotlight with several noteworthy developments. The company announced that its drug TREMFYA met key endpoints in a Phase 3b study for treating active psoriatic arthritis, demonstrating reduced disease symptoms and slowed joint damage progression. Meanwhile, Goldman Sachs upgraded Johnson & Johnson’s stock rating from "Neutral" to "Buy," citing potential growth in its Innovative Medicine business and raising the price target to $172. UBS also maintained its Buy rating with a $180 target, highlighting positive trends in prescription growth and optimism for future approvals of TREMFYA for additional conditions. Additionally, RBC Capital Markets reaffirmed its Outperform rating with a $181 price target, focusing on the potential of the RYBREVANT plus LAZCLUZE treatment in the lung cancer market. These analyst perspectives come amid broader industry challenges, as President Trump announced plans for major tariffs on pharmaceuticals, which could impact the global supply chain and profitability. Investors are closely watching these developments as they navigate the complexities of the pharmaceutical landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.